EU Clinical Trial Information System (CTIS)

Brand Logo

Brand Logo Light

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

I searched for some studies on AstraZeneca Clinical Trials, and found these studies that may also be of interest to you.
Here is the link to my search results

Official Title

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

To capture safety when Forxiga is administered to patients  with HF in clinical practice after launch.

Forxiga HF General Drug Use-Results Study

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch. 
(1)	ADRs which are unexpected from the precautions for use
(2)	Understanding of incidence of ADRs during use of Forxiga in the real world setting
(3)	Factors possibly having an impact on the safety

CTIS Number

EudraCT Number

NCT ID

Patient Level Data

Therapeutic Area

Research Site

Forxiga Tablets General Drug Use-Results Study in patients with HF

Development of ADRs by unexpected from “Precautions for Use” of Forxiga JPI, by SOC, by patient demography and by treatment

Forxiga HF General Drug Use-Results Study

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

Trial Results Summaries

Contacts

Contact